Pharma
Medicilon completed full sets of non-clinical research projects for new drugs such as ophthalmic solutions or intravitreal injections
Medicilon has been conducting comprehensive non-clinical research for ophthalmic drugs since 2013, with extensive experience from active pharmaceutical ingredients and formulations to pharmacodynamics, pharmacokinetics, and safety assessments, and has contributed to the approval of mult...
Medicilon large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development
With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. ...
Strategies for coping with ILD
Interstitial lung disease (ILD) is a chronic and life-limiting lung disease with no curative options which can take a significant emotional toll on sufferers. A diagnosis of ILD comes with feelings of anxiety and uncertainty about the future. As the condition progresses, patients are al...
High opacity micro 3D printing - Tough Carbon Black
Revolutionizing Micro 3D Printing with Tough Carbon Black
Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent y...
Medicilon neural system disease models help our clients advance novel drug development
Medicilon Pharmacodynamics Department can deliver multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsant, anti-Parkinson's drugs, and anti-schizophrenia drugs. Those models can effectively e...
Guardtech Group hoping to end golden year with more success at SME National Business Awards
Suffolk contamination control experts looking to add Best Enterprising Business prize to epic 2024 awards haul at glitzy Wembley Stadium showpiece on 6 December ...
Analytics for clinical development strategy: Integrated optimization of an oncology program
Achieving a return on invested capital (ROIC) that exceeds the cost of capital remains a challenge for pharmaceutical R&D. To make progress, there needs to be consistent and rigorous modeling of the clinical and commercial determinants of ROIC. In the second of three articles, CRA’...
CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?
Aduhelm was the first FDA-approved disease-modifying treatment for Alzheimer’s, sparking debate among providers, regulators, and patients. Aduhelm received a controversial accelerated approval from the FDA in June 2021, a decision that balanced the lack of consensuses among the scientif...
Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D
Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This...